Skip to main content
Clinical Trials/EUCTR2021-002784-21-SE
EUCTR2021-002784-21-SE
Active, Not Recruiting
Phase 1

Botulinum toxin type A as treatment for chronic myogenous orofacial pain - a radomized controlled, double-blind clinical trial

Västra Götalandsregionen0 sites72 target enrollmentFebruary 9, 2022

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Chronic myalgia (>6months) in the facial region.
Sponsor
Västra Götalandsregionen
Enrollment
72
Status
Active, Not Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 9, 2022
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age at least 18years
  • Written consent
  • Adequate communicative skills in Swedish
  • Myalgia as defined by DC/TMD
  • Prior conservative treatment for at least 6months with a minimum of information on diagnosis and prognosis, patient councelling, instruction in resting the jaw, biofeedback training and jaw exercise
  • Subjective degree of pain \= 40mm on a 100mm VAS scale
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 40

Exclusion Criteria

  • Pain of dental origin
  • Athritis as defined by DC/TMD expanded taxonomy
  • Rheumatic disease diagnosed by physician (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis / Bechterew's disease, reactive arthritis, juvenile idiopathic arthritis)
  • Neuropathic pain, diagnosed by physician, of central / peripheral genesis or infectious / inflammatory genesis (eg stroke, multiple sclerosis, brain damage, traumatic or surgically triggered facial injury, tumor\-induced nerve involvement, postherpetic neuralgia, trigeminal neuralgia, neuroborreliosis
  • Impaired neuromuscular transmission e.g. myasthenia gravis or Eaton Lambert's syndrome or peripheral motor neuropathic and neurological diseases (eg amyotrophic lateral sclerosis or motor neuropathy), diagnosed by physician
  • Hypersensitivety or allergy to any botulinum toxin product or to any of the components in the formulation
  • Pregnancy / breastfeeding or planned pregnancy. Women of childbearing potential must use highly effective contraceptives i.e oral, intravaginal or transdermal combined (estrogen and progestogen containing) hormonal contraception, oral, injectable or implantablie progestogen\-only hormonal contraception, intrauterine device (IUD), intrauterine hormone\-releasing system ( IUS) 2, bilateral tubal occlusion, vasectomised partner. CE\- approved pregnancy tests are handed to the patient for monthly tests up to 6 months after the last injection (a total of 11 tests).
  • Infection at site of injection
  • Ongoing treatment with aminoglycosides, cholinesterase inhibitors or muscle relaxants
  • Prior or ongoing treatment with botulinum toxin A of any serotype

Outcomes

Primary Outcomes

Not specified

Similar Trials